Spoken approach
say this aloud Free preview- This is a patient with type 2 diabetes and progressive chronic kidney disease, a high-risk situation requiring a comprehensive, evidence-based management plan to slow GFR decline and reduce cardiovascular events.
- My immediate priority is to implement a multi-pillar strategy based on the latest KDIGO guidelines.
- First, for kidney and cardiovascular protection, I will start an SGLT2 inhibitor, such as empagliflozin 10 mg or dapagliflozin 10 mg daily, as the patient's eGFR is above 20. This is a cornerstone of therapy, independent of HbA1c.
+ 7 more steps of the spoken answer for subscribers